News & Updates

New drug applications approved by US FDA as of 16 - 31 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of estrogen replacement therapy appears to yield a risk-lowering effect on gastric and colorectal cancers, as reported in a retrospective study.

Tumour burden, as assessed by imaging techniques, appears to substantially influence outcomes in patients with recurrent or metastatic head and neck cancer (RM-HNC) treated with immune checkpoint inhibitors (ICI), a recent study has found.

Salivary levels of miRNA-21 and miRNA-31 appear to correlate with the onset and progression of oral potentially malignant disorders (OPMD) and could be used as noninvasive biomarkers for screening, a recent study has found.

The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.